Cellectis S.A. (EPA:ALCLS)
France · Delayed Price · Currency is EUR | Market Cap | 227.82M +149.3% |
| Revenue (ttm) | 70.36M +129.0% |
| Net Income | -30.13M |
| EPS | -0.30 |
| Shares Out | 72.33M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 214,196 |
| Average Volume | 210,034 |
| Open | 3.060 |
| Previous Close | 3.190 |
| Day's Range | 3.045 - 3.240 |
| 52-Week Range | 1.012 - 4.840 |
| Beta | 2.85 |
| RSI | 42.61 |
| Earnings Date | Mar 19, 2026 |
About Cellectis
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric an... [Read more]
Financial Performance
In 2024, Cellectis's revenue was $49.22 million, an increase of 435.37% compared to the previous year's $9.19 million. Losses were -$36.76 million, -63.62% less than in 2023.
Financial numbers in USD Financial StatementsNews
Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS, NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to deve...
Monthly information on share capital and company voting rights
(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of General Regulation of the French financial markets authority)
Monthly information on share capital and company voting rights
(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of General Regulation of the French financial markets authority)
Cellectis (CLLS) Receives New 'Buy' Rating from Clear Street | CLLS Stock News
Cellectis (CLLS) Receives New 'Buy' Rating from Clear Street | CLLS Stock News
Cellectis: Showcasing Encouraging Data, But Still Early To Make A Run Like This
Allogene Arbitration Victory Pressures Cellectis Shares Tuesday
Cellectis shares fell after Allogene cited ... Full story available on Benzinga.com
Allogene Arbitration Victory Pressures Cellectis Shares Tuesday
Shares of Cellectis S.A. (NASDAQ: CLLS) tanked on Tuesday after Allogene Therapeutics Inc. (NASDAQ: ALLO) cited a favorable arbitration outcome for partner Servier in its dispute with Cellectis relate...
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis
Arbitration Ruling Reaffirms Allogene's Full Control of Cemacabtagene Ansegedleucel (Cema-Cel) Decision Reconfirms Allogene's Expanded Sub-License Covering EU and UK Rights with Options for Japan and ...
Cellectis (CLLS) Arbitration Outcome Adjusts License Agreement
Cellectis (CLLS) Arbitration Outcome Adjusts License Agreement
Cellectis Announces Arbitral Decision in Dispute with Servier
NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to deve...
Cellectis' Allogeneic CAR-T Potential Still Justifies A 'Buy'
CELLS develops off-the-shelf TALEN-edited CAR-T therapies. Its main in-house asset is lasme-cel for r/r B-ALL and eti-cel for r/r B-cell NHL. Early data show that lasme-cel reached impressive ORRs in ...
ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL
NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to deve...
Monthly information on share capital and company voting rights
(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of General Regulation of the French financial markets authority)
Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells
NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to deve...
Cellectis Q3 2025 Earnings Preview
Cellectis (CLLS) Reports Strong Q3 Revenue Growth and Promising Clinical Data
Cellectis (CLLS) Reports Strong Q3 Revenue Growth and Promising Clinical Data
Cellectis GAAP EPS of $0.01 beats by $0.24, revenue of $37.16M
Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update
Presented data underscore the potential of lasme-cel (UCART22) and eti-cel (UCART20x22) to improve outcomes in r/r B-ALL and r/r NHL: Lasme-cel in r/r B-ALL (BALLI-01) ORR of 68% with lasme-cel Proces...
Cellectis Earnings Preview
Cellectis (NASDAQ: CLLS) will release its quarterly earnings report on Friday, 2025-11-07. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Cellectis to report an ...
Cellectis (CLLS) to Present Key Research at 2025 ASH Meeting
Cellectis (CLLS) to Present Key Research at 2025 ASH Meeting
Cellectis to Present a Development Update for eti-cel at ASH 2025
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to deve...
Cellectis to Report Third Quarter Financial Results on November 7, 2025
NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to devel...
CLLS: Analyst Raises Price Target Significantly for Cellectis | CLLS Stock News
CLLS: Analyst Raises Price Target Significantly for Cellectis | CLLS Stock News
Cellectis' R&D Day Highlights Lasme-cel's Potential to Address Significant Unmet Need for Patients with r/r B-ALL
○ Efficacy: ORR of 68% with lasme-cel Process 2 (n=22), 83% at RP2D (n=12) and 100% in the target Phase 2 population (n=9)
Top 2 Health Care Stocks That May Keep You Up At Night This Month
As of Oct. 16, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.